IN2014CN00817A - - Google Patents
Info
- Publication number
- IN2014CN00817A IN2014CN00817A IN817CHN2014A IN2014CN00817A IN 2014CN00817 A IN2014CN00817 A IN 2014CN00817A IN 817CHN2014 A IN817CHN2014 A IN 817CHN2014A IN 2014CN00817 A IN2014CN00817 A IN 2014CN00817A
- Authority
- IN
- India
- Prior art keywords
- isoquinolin
- yloxy
- piperidin
- preparation
- relates
- Prior art date
Links
- KMNVOGVCCZNVNU-UHFFFAOYSA-N 6-piperidin-4-yloxy-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C=1C=C2C(=O)NC=CC2=CC=1OC1CCNCC1 KMNVOGVCCZNVNU-UHFFFAOYSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305890 | 2011-07-08 | ||
| EP11306033 | 2011-12-29 | ||
| PCT/EP2012/062431 WO2013007518A1 (en) | 2011-07-08 | 2012-06-27 | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00817A true IN2014CN00817A (enExample) | 2015-04-03 |
Family
ID=46397257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN817CHN2014 IN2014CN00817A (enExample) | 2011-07-08 | 2012-06-27 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8710078B2 (enExample) |
| EP (1) | EP2729460B1 (enExample) |
| JP (1) | JP6357100B2 (enExample) |
| KR (1) | KR102013566B1 (enExample) |
| CN (1) | CN103781778B (enExample) |
| AU (1) | AU2012283276B2 (enExample) |
| CA (1) | CA2843773C (enExample) |
| CO (1) | CO6870040A2 (enExample) |
| CY (1) | CY1118326T1 (enExample) |
| DK (1) | DK2729460T3 (enExample) |
| ES (1) | ES2568245T3 (enExample) |
| HR (1) | HRP20160356T1 (enExample) |
| HU (1) | HUE027309T2 (enExample) |
| IN (1) | IN2014CN00817A (enExample) |
| MA (1) | MA35340B1 (enExample) |
| PH (1) | PH12014500289B1 (enExample) |
| PL (1) | PL2729460T3 (enExample) |
| RU (1) | RU2619129C2 (enExample) |
| SG (1) | SG2014007520A (enExample) |
| SI (1) | SI2729460T1 (enExample) |
| WO (1) | WO2013007518A1 (enExample) |
| ZA (1) | ZA201400941B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2729460T3 (en) * | 2011-07-08 | 2016-04-18 | Sanofi Sa | Crystalline solvates of 6- (piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride |
| KR20250036929A (ko) | 2022-08-01 | 2025-03-14 | 발로 헬스, 인코포레이티드 | 6-치환된-1-(2h)-아이소퀴놀리논 및 중간체 화합물의 제조 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| PT1910333E (pt) * | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7478743B2 (en) | 2006-02-28 | 2009-01-20 | Holley Jr John M | Carton for tapered and cylindrical articles |
| JP5421783B2 (ja) * | 2006-12-27 | 2014-02-19 | サノフイ | Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体 |
| ATE502027T1 (de) * | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
| KR20100103646A (ko) * | 2007-12-26 | 2010-09-27 | 사노피-아벤티스 | ６치환된１（２ｈ）이소퀴놀리논의 제조 방법 |
| DK2729460T3 (en) * | 2011-07-08 | 2016-04-18 | Sanofi Sa | Crystalline solvates of 6- (piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride |
-
2012
- 2012-06-27 DK DK12730523.3T patent/DK2729460T3/en active
- 2012-06-27 CN CN201280043723.9A patent/CN103781778B/zh active Active
- 2012-06-27 HR HRP20160356TT patent/HRP20160356T1/hr unknown
- 2012-06-27 HU HUE12730523A patent/HUE027309T2/en unknown
- 2012-06-27 ES ES12730523.3T patent/ES2568245T3/es active Active
- 2012-06-27 KR KR1020147003354A patent/KR102013566B1/ko active Active
- 2012-06-27 IN IN817CHN2014 patent/IN2014CN00817A/en unknown
- 2012-06-27 US US13/534,815 patent/US8710078B2/en active Active
- 2012-06-27 PH PH1/2014/500289A patent/PH12014500289B1/en unknown
- 2012-06-27 SI SI201230516A patent/SI2729460T1/sl unknown
- 2012-06-27 AU AU2012283276A patent/AU2012283276B2/en active Active
- 2012-06-27 SG SG2014007520A patent/SG2014007520A/en unknown
- 2012-06-27 WO PCT/EP2012/062431 patent/WO2013007518A1/en not_active Ceased
- 2012-06-27 EP EP12730523.3A patent/EP2729460B1/en active Active
- 2012-06-27 PL PL12730523T patent/PL2729460T3/pl unknown
- 2012-06-27 CA CA2843773A patent/CA2843773C/en active Active
- 2012-06-27 RU RU2014104358A patent/RU2619129C2/ru active
- 2012-06-27 JP JP2014517674A patent/JP6357100B2/ja active Active
-
2014
- 2014-02-05 CO CO14024164A patent/CO6870040A2/es not_active Application Discontinuation
- 2014-02-06 MA MA36739A patent/MA35340B1/fr unknown
- 2014-02-07 ZA ZA2014/00941A patent/ZA201400941B/en unknown
- 2014-04-04 US US14/245,451 patent/US20140221656A1/en not_active Abandoned
-
2016
- 2016-04-12 CY CY20161100305T patent/CY1118326T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013007518A1 (en) | 2013-01-17 |
| PL2729460T3 (pl) | 2016-07-29 |
| CO6870040A2 (es) | 2014-02-20 |
| PH12014500289A1 (en) | 2014-03-24 |
| RU2014104358A (ru) | 2015-08-20 |
| MA35340B1 (fr) | 2014-08-01 |
| US20140221656A1 (en) | 2014-08-07 |
| AU2012283276A1 (en) | 2014-02-27 |
| CN103781778A (zh) | 2014-05-07 |
| CY1118326T1 (el) | 2017-06-28 |
| HK1192546A1 (zh) | 2014-08-22 |
| JP6357100B2 (ja) | 2018-07-11 |
| HUE027309T2 (en) | 2016-10-28 |
| CA2843773C (en) | 2018-11-06 |
| SI2729460T1 (sl) | 2016-05-31 |
| HRP20160356T1 (hr) | 2016-05-06 |
| SG2014007520A (en) | 2014-07-30 |
| CA2843773A1 (en) | 2013-01-17 |
| KR102013566B1 (ko) | 2019-08-23 |
| PH12014500289B1 (en) | 2019-06-28 |
| NZ620864A (en) | 2015-08-28 |
| US20130012444A1 (en) | 2013-01-10 |
| DK2729460T3 (en) | 2016-04-18 |
| AU2012283276B2 (en) | 2014-07-24 |
| KR20140045550A (ko) | 2014-04-16 |
| EP2729460A1 (en) | 2014-05-14 |
| RU2619129C2 (ru) | 2017-05-12 |
| CN103781778B (zh) | 2015-10-07 |
| JP2014518235A (ja) | 2014-07-28 |
| ES2568245T3 (es) | 2016-04-28 |
| US8710078B2 (en) | 2014-04-29 |
| EP2729460B1 (en) | 2016-01-13 |
| ZA201400941B (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706745B (en) | Forms of rifaximin and usage thereof | |
| MY160625A (en) | Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation | |
| GEP20247677B (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| IN2015DN01156A (enExample) | ||
| TN2011000673A1 (en) | Bace inhibitors | |
| IN2014DN10670A (enExample) | ||
| PH12013500870A1 (en) | Heterocyclic compounds and uses thereof | |
| UA111186C2 (uk) | Способи та композиції для одержання норибогаїну з воакангіну | |
| JO2887B1 (en) | Spiro-pyridine compounds as ORL-1 receptor antagonists | |
| PT2785692T (pt) | Anilinas substituídas como antagonistas do ccr(4) | |
| IN2012DN01292A (enExample) | ||
| MY167208A (en) | Partially Hydrolyzed Casein-Whey Nutritional Compositions for Reducing the Onset of Allergies | |
| IN2014CN03854A (enExample) | ||
| GEP201706626B (en) | Synthesis of (s)-nifuratel | |
| IL221471A0 (en) | Process for the preparation of alpha form of imatinib mesylate | |
| IN2013MN02414A (enExample) | ||
| MX351631B (es) | Composiciones y metodos para reducir la incidencia de trastornos digestivos equinos. | |
| MX347541B (es) | Analogos de acido sialico. | |
| GB201107985D0 (en) | Process | |
| IN2012DN01929A (enExample) | ||
| IN2014DN08296A (enExample) | ||
| IN2014DN09451A (enExample) | ||
| PH12013500210A1 (en) | Highly crystalline valsartan | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| IN2012DN02698A (enExample) |